Mein Warenkorb

IL-12 R beta 1

IL-12 R beta 1 Molekülinformation

Englischer NameInterleukin-12 receptorAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel9Target-AliasReceptors, Interleukin-12
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameInterleukin-12 receptor
Target-AliasReceptors, Interleukin-12
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel9
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

IL-12 R beta 1 Molekülhintergrund

The human IL-12 R subunit is a member of the cytokine receptor superfamily and the functional high-affinity IL-12R is composed of at least two beta-type cytokine receptor subunits, each independently exhibiting a low affinity for IL-12. IL-12 R beta 1 (Interleukin-12 receptor subunit beta-1) is also known as IL-12RB1, CD212. Functions as an interleukin receptor which binds interleukin-12 with low affinity and is involved in IL12 transduction. Associated with IL12RB2 it forms a functional, high affinity receptor for IL12. Associates also with IL23R to form the interleukin-23 receptor which functions in IL23 signal transduction probably through activation of the Jak-Stat signaling cascade.

IL-12 R beta 1 Molekülalias

IL-12 R beta 1,IL12RB1,CD212,IL12R,IL12RB,IL-12RB1

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
KLT-1101KLT-1101Phase 2 ClinicalKang Litai Pharmaceutical Co LtdLeukopenia; Melanoma; Sarcoma, Kaposi; Solid tumours; Thrombocytopenia
Details
Edodekin alfaRO 247472; YM 01CPhase 2 ClinicalF. Hoffmann-La Roche Ltd, Valeant, Wistar InstituteAbdominal Neoplasms; Asthma; Bacterial Infections; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Graft vs Host Disease; Hepatitis B; Hepatitis C; HIV Infections; Leishmaniasis; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Malaria; Melanoma; Neoplasms; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
RTX-224RTX-224Phase 2 ClinicalRubius Therapeutics IncCarcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms
Details
KB-707KB707; KB-707Phase 2 ClinicalKrystal Biotech IncCarcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Neoplasms; Skin Melanoma; Solid tumours
Details
ASP-9801ASP-9801Phase 1 ClinicalAstellas Pharma IncNeoplasm Metastasis; Neoplasms; Solid tumours
Details
Tolododekin AlfaANK101; ANK-101Phase 1 ClinicalAnkyra Therapeutics IncCarcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Rejection of renal transplantation; Skin Neoplasms; Soft Tissue Injuries; Solid tumours
Details
CLN-617CLN-617Phase 1 ClinicalCullinan Therapeutics IncSolid tumours
Details
SON-1010SON-1010Phase 1 ClinicalSonnet Biotherapeutics IncCarcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Sarcoma; Solid tumours
Details
phIL12 GETPhase 1 ClinicalInstitute Of Oncology LjubljanaCarcinoma, Basal Cell
Details

Produktrezensionen

  • K***n2024-10-05
    0Menschen mögen
    I’ve been using the IL12 receptor protein from Acro Biosystem in my antibody discovery research, and I’m highly satisfied with its quality. The protein exhibits excellent stability and bioactivity, which has been crucial in my experiments targeting immune responses. It’s been a reliable reagent, showing consistent results across various assays. I highly recommend this product for anyone involved in immunological research, particularly in therapeutic antibody development.
  • Molekülinformation
  • Produktliste
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns